Critical Care Services Comprehensive Study by Application (Intensive Care Units, Neonatal Intensive Care Units, Pediatric Intensive Care Units, Coronary Care Units), Critical care equipment (Ventilator, CPMs, Enclosure systems, Pumps, Suction devices, Others), Disease (Central Nervous System Failure, Circulatory Failure, Shock, Metabolic, Respiratory Failure), End user (Hospitals, Clinics) Players and Region - Global Market Outlook to 2026

Critical Care Services Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Critical Care Services Market?

Critical care systems helps the patients who are facing the life threatening situations. It takes care of organ systems and hence improves the health conditions.There is a team of health care professionals who handles the critical care systems which are equipped and designed to monitor and treat the conditions. Additionally, the patients at risk of organ failure like lungs, heart and kidneys are taken care with this services. The critical care units includes Intensive care units, High dependency units, and critical care outreach and post intensive care service. According to National Center for Biotechnology Information and U.S. National Library of Medicine, United States has the highest ICU beds per 100,000 people that is 20-31.7 and spends USD 7,164 per capita. United States is followed by Canada with 13.5 ICU beds per 100,000 people and spends USD 3,867 per capita.

The market study is being classified, by Application (Intensive Care Units, Neonatal Intensive Care Units, Pediatric Intensive Care Units and Coronary Care Units) and major geographies with country level break-up.

Thermo Fisher Scientific (United States), Merck (United States), BioMed Central (United Kingdom), CSL Behring (United States), Shire (United States), Grifols (Spain), Kedrion Biopharma (Spain), Octapharma (Switzerland), Bayer HealthCare (Germany) and Mitsubishi Tanabe Pharma (Japan) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Rockwell Medical (United States), Shanghai RAAS (China), China Biologic Products (China), Cosmo Pharmaceuticals (Italy), King Pharmaceuticals (United States) and REVO Biologics (United States).

The global Critical care service market is concentrated as it consists of major players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Critical Care Services market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Critical Care Services market by Type, Application and Region.

On the basis of geography, the market of Critical Care Services has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing geriatric population and emergence of new diseases are fueling the market. The new diseases are emerging such as COVID 19 and the patients with these diseases require hospitalizations and critical care services as well. With the increasing number of infected patients, number of hospitalizations is increasing which is having positive impact on the market.

Market Trend
  • Increased Development of Recombinant Products for Critical Care Use.
  • Technological Advancements in Critical Care Systems

Restraints
  • High Costs Associated with the equipment and treatment of disease as well

Opportunities
  • Heavy Investments in Healthcare Facilities Providing Modern Medical Treatments
  • Increasing Number of Multi-Speciality Hospitals is creating an Opportunity
  • Presence of Cheaper Equipment of Critical Care Systems

Challenges
  • Lack of Trained Staff can Hamper the Growth of Market


Market Leaders and some development strategies
In 2019, Cornerstone has acquired Southland home health and launched Joint Venture with Lake Charles memorial health systems to expand its capabilities to home health.
On 28th January 2020, Drager has launched new ventilators which are new Evita V600 and V800 ventilators. These are designed to support daily clinical tasks in ICU. Its menu access to both settings and clinical data provides quick and safe operation in stressful situation. This will bring difference in efficiency during critical care services. and On 21st February 2018, Philips has launched healthcare home services in Chennai with ICU home. This service will provide Intensive care unit equipment and high quality medical care at home for patients.


Key Target Audience
Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organisations

Report Objectives / Segmentation Covered

By Application
  • Intensive Care Units
  • Neonatal Intensive Care Units
  • Pediatric Intensive Care Units
  • Coronary Care Units
By Critical care equipment
  • Ventilator
  • CPMs
  • Enclosure systems
  • Pumps
  • Suction devices
  • Others

By Disease
  • Central Nervous System Failure
  • Circulatory Failure
  • Shock
  • Metabolic
  • Respiratory Failure

By End user
  • Hospitals
  • Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing geriatric population and emergence of new diseases are fueling the market. The new diseases are emerging such as COVID 19 and the patients with these diseases require hospitalizations and critical care services as well. With the increasing number of infected patients, number of hospitalizations is increasing which is having positive impact on the market.
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Staff can Hamper the Growth of Market
    • 3.4. Market Trends
      • 3.4.1. Increased Development of Recombinant Products for Critical Care Use.
      • 3.4.2. Technological Advancements in Critical Care Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
  • 5. Global Critical Care Services, by Application, Critical care equipment, Disease, End user and Region (value) (2015-2020)
    • 5.1. Introduction
  • 6. Critical Care Services: Manufacturers/Players Analysis
    • 6.1. Company Profile
      • 6.1.1. Thermo Fisher Scientific (United States)
        • 6.1.1.1. Business Overview
        • 6.1.1.2. Products/Services Offerings
        • 6.1.1.3. Financial Analysis
        • 6.1.1.4. SWOT Analysis
      • 6.1.2. Merck (United States)
        • 6.1.2.1. Business Overview
        • 6.1.2.2. Products/Services Offerings
        • 6.1.2.3. Financial Analysis
        • 6.1.2.4. SWOT Analysis
      • 6.1.3. BioMed Central (United Kingdom)
        • 6.1.3.1. Business Overview
        • 6.1.3.2. Products/Services Offerings
        • 6.1.3.3. Financial Analysis
        • 6.1.3.4. SWOT Analysis
      • 6.1.4. CSL Behring (United States)
        • 6.1.4.1. Business Overview
        • 6.1.4.2. Products/Services Offerings
        • 6.1.4.3. Financial Analysis
        • 6.1.4.4. SWOT Analysis
      • 6.1.5. Shire (United States)
        • 6.1.5.1. Business Overview
        • 6.1.5.2. Products/Services Offerings
        • 6.1.5.3. Financial Analysis
        • 6.1.5.4. SWOT Analysis
      • 6.1.6. Grifols (Spain)
        • 6.1.6.1. Business Overview
        • 6.1.6.2. Products/Services Offerings
        • 6.1.6.3. Financial Analysis
        • 6.1.6.4. SWOT Analysis
      • 6.1.7. Kedrion Biopharma (Spain)
        • 6.1.7.1. Business Overview
        • 6.1.7.2. Products/Services Offerings
        • 6.1.7.3. Financial Analysis
        • 6.1.7.4. SWOT Analysis
      • 6.1.8. Octapharma (Switzerland)
        • 6.1.8.1. Business Overview
        • 6.1.8.2. Products/Services Offerings
        • 6.1.8.3. Financial Analysis
        • 6.1.8.4. SWOT Analysis
      • 6.1.9. Bayer HealthCare (Germany)
        • 6.1.9.1. Business Overview
        • 6.1.9.2. Products/Services Offerings
        • 6.1.9.3. Financial Analysis
        • 6.1.9.4. SWOT Analysis
      • 6.1.10. Mitsubishi Tanabe Pharma (Japan)
        • 6.1.10.1. Business Overview
        • 6.1.10.2. Products/Services Offerings
        • 6.1.10.3. Financial Analysis
        • 6.1.10.4. SWOT Analysis
  • 7. Global Critical Care Services Sale, by Application, Critical care equipment, Disease, End user and Region (value) (2021-2026)
    • 7.1. Introduction
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Company Basic Information, Sales Area and Its Competitors
  • Table 2. Company Basic Information, Sales Area and Its Competitors
  • Table 3. Company Basic Information, Sales Area and Its Competitors
  • Table 4. Company Basic Information, Sales Area and Its Competitors
  • Table 5. Company Basic Information, Sales Area and Its Competitors
  • Table 6. Company Basic Information, Sales Area and Its Competitors
  • Table 7. Company Basic Information, Sales Area and Its Competitors
  • Table 8. Company Basic Information, Sales Area and Its Competitors
  • Table 9. Company Basic Information, Sales Area and Its Competitors
  • Table 10. Company Basic Information, Sales Area and Its Competitors
  • Table 11. Research Programs/Design for This Report
  • Table 12. Key Data Information from Secondary Sources
  • Table 13. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 5. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 6. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 7. Merck (United States) Revenue: by Geography 2020
  • Figure 8. BioMed Central (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 9. BioMed Central (United Kingdom) Revenue: by Geography 2020
  • Figure 10. CSL Behring (United States) Revenue, Net Income and Gross profit
  • Figure 11. CSL Behring (United States) Revenue: by Geography 2020
  • Figure 12. Shire (United States) Revenue, Net Income and Gross profit
  • Figure 13. Shire (United States) Revenue: by Geography 2020
  • Figure 14. Grifols (Spain) Revenue, Net Income and Gross profit
  • Figure 15. Grifols (Spain) Revenue: by Geography 2020
  • Figure 16. Kedrion Biopharma (Spain) Revenue, Net Income and Gross profit
  • Figure 17. Kedrion Biopharma (Spain) Revenue: by Geography 2020
  • Figure 18. Octapharma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Octapharma (Switzerland) Revenue: by Geography 2020
  • Figure 20. Bayer HealthCare (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Bayer HealthCare (Germany) Revenue: by Geography 2020
  • Figure 22. Mitsubishi Tanabe Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Mitsubishi Tanabe Pharma (Japan) Revenue: by Geography 2020
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • Merck (United States)
  • BioMed Central (United Kingdom)
  • CSL Behring (United States)
  • Shire (United States)
  • Grifols (Spain)
  • Kedrion Biopharma (Spain)
  • Octapharma (Switzerland)
  • Bayer HealthCare (Germany)
  • Mitsubishi Tanabe Pharma (Japan)
Additional players considered in the study are as follows:
Rockwell Medical (United States) , Shanghai RAAS (China) , China Biologic Products (China) , Cosmo Pharmaceuticals (Italy) , King Pharmaceuticals (United States) , REVO Biologics (United States)
Select User Access Type

Key Highlights of Report


May 2021 204 Pages 88 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing geriatric population and emergence of new diseases are fueling the market. The new diseases are emerging such as COVID 19 and the patients with these diseases require hospitalizations and critical care services as well. With the increasing number of infected patients, number of hospitalizations is increasing which is having positive impact on the market." is seen as one of major growth factors of Critical Care Services Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Critical Care Services Market Report?